The prognosis (survival) for Acute Lymphoblastic Leukemia (ALL) varies significantly depending on several factors, including the patient's age, disease risk group, ALL subtype, and whether a stem cell transplant has been performed. According to clinical studies, 5-year survival rates have been reported across a wide range, from 20% to 65%. Complete cure is considered achieved in ALL patients whose disease has not relapsed for 5 years.